Didemnin B vs Dolastatin 10
Head-to-head comparison of Didemnin B (Didemnin B) and Dolastatin 10 (Dolastatin 10) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Didemnin B | Dolastatin 10 |
|---|---|---|
| Category | Experimental | Experimental |
| Full Name | Didemnin B | Dolastatin 10 |
| Molecular Weight | 1112.4 Da | 771.0 Da |
| Half-Life | N/A | N/A |
| Amino Acids | N/A | 5 |
| Typical Dose | 0.05-2 mg/m2 IV in early trials | N/A in humans; subnanomolar to low-nanomolar in vitro |
| Route | Intravenous | Intravenous |
| Purity | ≥98% | ≥98% |
| Studies Count | 120 | 300 |
| Research Status | Clinical | Pre-clinical |
Didemnin B Benefits
- ✓antineoplastic
- ✓antiviral
- ✓pro-apoptotic
- ✓immunomodulatory
Dolastatin 10 Benefits
- ✓antineoplastic
- ✓microtubule disruption
- ✓antimitotic
- ✓ADC payload scaffold
Didemnin B Dosing
historic IV phase I/II oncology regimens|dose escalation in early trials|no approved dosing regimen
Dolastatin 10 Dosing
research-grade in vitro nanomolar use|early IV oncology exploration|no approved dosing regimen
Didemnin B Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠myelosuppression
Dolastatin 10 Side Effects
- ⚠peripheral neuropathy
- ⚠neutropenia
- ⚠fatigue
Research Overview
Didemnin B
Didemnin B showed strong cytotoxic and antiviral activity in early literature and became an important scaffold for later marine drug development. Its clinical progress was limited by toxicity, but it remains highly cited as a foundational marine depsipeptide.
Dolastatin 10
Dolastatin 10 became famous for extreme cytotoxic potency and its ability to block tubulin polymerization. Although the native compound itself did not become a standard therapy, it inspired a major class of clinically important auristatin-based payloads.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.